Anika Therapeutics (ANIK) Cash from Operations Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 61.90% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -22.14% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 0.46% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 125.00% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 425.00% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -267.74% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -18.09% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.33% |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -3,627.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,627.69% |
| Dec 31, 2025 | 193.11% |
| Sep 30, 2025 | 36.96% |
| Jun 30, 2025 | 82.32% |
| Mar 31, 2025 | -3.17% |
| Dec 31, 2024 | -56.51% |
| Sep 30, 2024 | -22.65% |
| Jun 30, 2024 | 87.11% |
| Mar 31, 2024 | 96.52% |
| Dec 31, 2023 | 656.34% |
| Sep 30, 2023 | 139.39% |
| Jun 30, 2023 | -368.56% |
| Mar 31, 2023 | -93.58% |
| Dec 31, 2022 | -89.24% |
| Sep 30, 2022 | 31.38% |
| Jun 30, 2022 | -28.09% |
| Mar 31, 2022 | 23.12% |
| Dec 31, 2021 | 72.86% |
| Sep 30, 2021 | -64.84% |
| Jun 30, 2021 | 20.35% |